Efficacy of Metformin in Lean Women With Polycystic Ovary Syndrome

N/AUnknownNCT00319293

Aarhus University Hospital Skejby20 enrolled

Overview

Insulin resistance is an important feature of the polycystic ovary syndrome,and patiens are successfully treated with the insulin sensitizing agent metformin. The insulin resistance of lean patients with the syndrome is debated. In this study, we will study the change in insulin resistance, metabolic and hormonal factors after 3 months of metformin treatment in lean PCOS women.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Polycystic Ovary Syndrome

Interventions

MetforminDRUG

Eligibility

Sex: FEMALEMin age: 20 YearsMax age: 35 Years

Medical Language ↔ Plain English

Inclusion Criteria: * PCOS (Rotterdam criteria) * BMI \< 27 * No medication for 3 months Exclusion Criteria: * Pregnancy * Lactation * Other endocrinologic disease

Outcomes

Primary Outcomes

Insulin resistance

Hormonal factors

Metabolic factors

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.